1: Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022 Dec 17;400(10369):2210-2220. doi: 10.1016/S0140-6736(22)01990-0. PMID: 36528376.
2: Cookson J, Jonsson F. A new cholinergic mechanism for antipsychotics: emraclidine and M4 muscarinic receptors. Lancet. 2022 Dec 17;400(10369):2159-2161. doi: 10.1016/S0140-6736(22)02421-7. PMID: 36528365.
3: Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. Novel Compounds in the Treatment of Schizophrenia-A Selective Review. Brain Sci. 2023 Aug 11;13(8):1193. doi: 10.3390/brainsci13081193. PMID: 37626549; PMCID: PMC10452918.
4: Naguy A, Pridmore S, Alamiri B. The Future of Schizophrenia Psychopharmacotherapy: More Antipsychotic Atypicality? Guess So! Psychopharmacol Bull. 2023 Feb 28;53(1):55-57. PMID: 36873922; PMCID: PMC9981338.
